News

NCCN has received a research grant from AVEO and Astellas to evaluate the role of tivozanib in the treatment of solid tumors. Tivozanib is a potent, selective, long

Dey is conducting business as Mylan Specialty effective immediately, the company said. Dey Pharma will continue to be used as the legal entity until all required transition steps

Alpha-synuclein is a protein whose clumping is the pathological sign of Parkinson’s disease (PD). NeuroPhage Preclinical R&D senior vice president Kimberley S Gannon said the grant will provide

The solution has been selected by Interface Children & Family Services of Camarillo, Hope by the Sea of Laguna Niguel, Quapaw House, of Hot Springs, and St. Louis

The Canadian patent covers Polyanhydrides which links low molecular weight drugs containing a carboxylic acid group and an amine, thiol, alcohol or phenol group within their structure into

The study protocol was reviewed and cleared by the FDA and Health Canada. RedHill has submitted an IND to the FDA and Clinical Trial Application (CTA) to Health

The recall is announced due to post-release investigation of the manufacturing area which determined a potential elevated risk of a lack of sterility assurance for these specific lots,

Gemcitabine is indicated for first-line therapy for ovarian, breast, lung, and pancreatic cancers. Uman is expected to file an abbreviated new drug application (ANDA) for gemcitabine with the

Meridian Medical Technologies, a Pfizer subsidiary, has signed a settlement agreement with Intelliject and Sanofi that will resolve pending patent litigation related to Intelliject’s NDA for its epinephrine